External validation of a clinical prediction model in multiple sclerosis
暂无分享,去创建一个
V. Shaygannejad | S. Khoury | C. Malpas | C. Boz | R. Karabudak | T. Kalincik | R. Alroughani | T. Al-Harbi | S. Sharmin | M. Terzi | A. Soysal | R. Turkoglu | A. Altıntaş | B. Yamout | J. Inshasi | N. Shalaby | N. Moradi
[1] V. Shaygannejad,et al. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018 , 2021, CNS Drugs.
[2] P. Sørensen,et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network , 2021, Multiple sclerosis.
[3] J. Lechner-Scott,et al. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. , 2020, Neurology.
[4] M. Sormani,et al. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a , 2020, Neurology.
[5] M. Sormani,et al. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score , 2020, Multiple sclerosis.
[6] H. Tian,et al. A systematic review and meta-analysis , 2019 .
[7] E. Bernitsas,et al. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis , 2020, International journal of molecular sciences.
[8] J. Lechner-Scott,et al. Risk of secondary progressive multiple sclerosis: A longitudinal study , 2019, Multiple sclerosis.
[9] À. Rovira,et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS , 2019, Multiple sclerosis.
[10] M. Slee,et al. Early clinical markers of aggressive multiple sclerosis. , 2019, Brain : a journal of neurology.
[11] Markus R. Lange,et al. Predicting risk of secondary progression in multiple sclerosis: A nomogram , 2018, Multiple sclerosis.
[12] H. Butzkueven,et al. Genotype and Phenotype in Multiple Sclerosis—Potential for Disease Course Prediction? , 2018, Current Treatment Options in Neurology.
[13] À. Rovira,et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria , 2018, Brain : a journal of neurology.
[14] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[15] Pierre Grammond,et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response , 2017, Brain : a journal of neurology.
[16] J. Lechner-Scott,et al. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice , 2017, Multiple sclerosis.
[17] A. Traboulsee,et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. , 2017, Autoimmunity reviews.
[18] L. Kappos,et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. , 2016, Multiple sclerosis and related disorders.
[19] Gavin Giovannoni,et al. Brain health: time matters in multiple sclerosis. , 2016, Multiple sclerosis and related disorders.
[20] M. Filippi,et al. Assessing response to interferon-β in a multicenter dataset of patients with MS , 2016, Neurology.
[21] T. Derfuss,et al. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. , 2016, Multiple sclerosis and related disorders.
[22] Pierre Grammond,et al. Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis , 2016, Annals of neurology.
[23] À. Rovira,et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. , 2015, Brain : a journal of neurology.
[24] M. Sormani,et al. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta‐analysis of randomized trials , 2015, European journal of neurology.
[25] B Stubinski,et al. Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.
[26] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[27] J Sastre-Garriga,et al. Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.
[28] L. Kappos,et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.
[29] Russell E. Glasgow,et al. Evaluating the Relevance, Generalization, and Applicability of Research , 2006, Evaluation & the health professions.
[30] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[31] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.